IONS – ionis pharmaceuticals, inc. (US:NASDAQ)

News

Lou Gehrig's Disease Pipeline Landscape Report 2024: Therapeutic Assessment of 80+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks [Yahoo! Finance]
ExeVir Announces Michael Garrett as New Chief Executive Officer [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Piper Sandler from $65.00 to $62.00. They now have an "overweight" rating on the stock.
Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com